Comparative Pharmacology
Head-to-head clinical analysis: FURALAN versus UROBAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FURALAN versus UROBAK.
FURALAN vs UROBAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
UROBAK (methenamine hippurate) is a prodrug that hydrolyzes to formaldehyde in acidic urine (pH ≤ 5.5). Formaldehyde denatures bacterial proteins and nucleic acids, exerting a broad-spectrum bacteriostatic effect. The hippurate component may enhance urinary acidification.
20 mg orally three times daily for 7 days.
500 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is 8–12 hours in adults with normal renal function; this supports twice-daily dosing. In patients with creatinine clearance <30 mL/min, half-life may be prolonged to 20–30 hours, requiring dose adjustment.
6-8 hours (prolonged in renal impairment).
Approximately 65–70% of an administered dose is excreted unchanged via renal glomerular filtration and tubular secretion; about 10–15% appears in bile as parent drug or glucuronide conjugate; up to 20% is eliminated in feces via unabsorbed fraction or biliary elimination.
Primarily renal (85% unchanged); 15% biliary/fecal.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective